A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Schuette, Wolfgang; Gröschel, A.; Sebastian, Martin; Andreas, Stefan; Müller, Thomas; Schneller, Folker; Guetz, Sylvia; Eschbach, C.; Bohnet, Sabine; Leschinger, M.; Reck, Martin

doi:10.1016/j.cllc.2012.10.001

Cited by 39 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 5 summarizes RRs and grade 3/4 HTox profile observed in the current and previously published studies. 4,[25][26][27][28][29] Although there was considerable variation in the observed toxicities and RRs, the incidence of anemia was highest in the current study as compared with others as well as greater than other hematological toxicities within our study.…”

Section: Discussioncontrasting

confidence: 68%

Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy

Singh

Aggarwal

Kaur

et al. 2017

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 68%

Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy

Singh

Aggarwal

Kaur

et al. 2017

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…31–34 In our study, nivolumab-related pneumonitis was as common as in the phase 1 trial. 6,7 By contrast with cytotoxic chemotherapy, 35 haematological toxic effects were infrequently reported with nivolumab. Moreover, a third or fewer of patients in our study had low-grade treatment-related fatigue, decreased appetite, nausea, asthenia, rash, or diarrhoea.…”

Section: Discussionmentioning

confidence: 99%

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Rizvi

Mazières

Planchard

et al. 2015

The Lancet Oncology

1,276

917

View full text Add to dashboard Cite

Summary Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer. Methods We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759. Findings Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7–22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2–4·8), and median duration of response was not reached (95% CI 8·31–not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7–10·9). 20 (17%) of 117 patients reported grade 3–4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease. Interpretation Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment. Funding Bristol-Myers Squibb.

show abstract

“…Recently, in nonsquamous histology, the combination of cisplatin (CDDP) and pemetrexed showed superior activity. 2,3 However, in chemotherapy-treated NSCLC, the duration of response is relatively short due to primary or acquired resistance to chemotherapy. 4 Patients with advanced disease may not derive any benefit from first-line chemotherapy, while they face significant treatment-related side effects.…”

mentioning

confidence: 99%

ATF2 contributes to cisplatin resistance in non‐small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway

Iacono

Monica

Vavalà

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

ATF2 is a transcription factor involved in stress and DNA damage. A correlation between ATF2 JNK-mediated activation and resistance to damaging agents has already been reported. The purpose of the present study was to investigate whether ATF2 may have a role in acquired resistance to cisplatin in non-small cell lung cancer (NSCLC). mRNA and protein analysis on matched cancer and corresponding normal tissues from surgically resected NSCLC have been performed. Furthermore, in NSCLC cell lines, ATF2 expression levels were evaluated and correlated to platinum (CDDP) resistance. Celastrol-mediated ATF2/cJUN activity was measured. High expression levels of both ATF2 transcript and proteins were observed in lung cancer specimens (p << 0.01, Log 2 (FC) 5 14.7). CDDP-resistant NSCLC cell lines expressed high levels of ATF2 protein. By contrast, Celastrol-mediated ATF2/cJUN functional inhibition restored the response to CDDP. Moreover, ATF2 protein activation correlates with worse outcome in advanced CDDP-treated patients. For the first time, it has been shown NSCLC ATF2 upregulation at both mRNA/protein levels in NSCLC. In addition, we reported that in NSCLC cell lines a correlation between ATF2 protein expression and CDDP resistance occurs. Altogether, our results indicate a potential increase in CDDP sensitivity, on Celastrolmediated ATF2/cJUN inhibition. These data suggest a possible involvement of ATF2 in NSCLC CDDP-resistance.Non-small cell lung cancer (NSCLC) is characterized by high incidence and mortality rate worldwide, being the most common subtypes represented by adenocarcinoma and squamous cell carcinoma. 1 Platinum-based chemotherapy in combination with other cytotoxic agents such as Gemcitabine, taxanes and vinorelbine represented the standard of care for unselected patients with advanced NSCLC. Recently, in nonsquamous histology, the combination of cisplatin (CDDP) and pemetrexed showed superior activity. 2,3 However, in chemotherapy-treated NSCLC, the duration of response is relatively short due to primary or acquired resistance to chemotherapy. 4 Patients with advanced disease may not derive any benefit from first-line chemotherapy, while they face significant treatment-related side effects. Consequently, it appears a logical approach to investigate alternative ways to increase the effectiveness outcomes of chemotherapy, through the identification of molecular features suggestive of a better therapeutic ratio.Activating transcription factor 2 (ATF2) is a member of the basic helix-loop-helix (b-ZIP) transcription factor family, whose transcriptional activities are mediated by stressactivated kinases JNK/p38 and activated by phosphorylation on threonine residues. 5,6 Independent of its transcriptional activity, ATF2 also plays an important role in the DNA damage response and in the regulation of intra-S-phase checkpoint (reviewed in Ref. 7). Several studies reported a correlation between ATF2/JNK-mediated activation and resistance to DNA damaging agents. Hayakawa et al. showed that stable expression of ATF...

show abstract

A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Cited by 39 publications

References 30 publications

Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy

Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

ATF2 contributes to cisplatin resistance in non‐small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway

Contact Info

Product

Resources

About